Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies
Curtis A. Lachowiez, Sanam Loghavi, Zhihong Zeng, et al.
Blood Cancer Discovery (2023) Vol. 4, Iss. 4, pp. 276-293
Open Access | Times Cited: 71

Showing 51-75 of 71 citing articles:

Mitochondria and Acute Leukemia: A Clinician’s Perspective
Prasad Iyer, Shaista Shabbir Jasdanwala, Karanpreet Singh Bhatia, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 17, pp. 9704-9704
Open Access | Times Cited: 1
Immunotherapeutic Potential of Mutated NPM1 for the Treatment of Acute Myeloid Leukemia
Jochen Greiner, Eithar Mohamed, Daniel Fletcher, et al.
Cancers (2024) Vol. 16, Iss. 20, pp. 3443-3443
Open Access | Times Cited: 1
The Cup Runneth Over: Treatment Strategies for Newly Diagnosed Acute Myeloid Leukemia
Jennifer H. Cooperrider, Navika Shukla, Mariam T. Nawas, et al.
JCO Oncology Practice (2022) Vol. 19, Iss. 2, pp. 74-85
Open Access | Times Cited: 6
Practical considerations in clinical application of WHO 5th and ICC classification schemes for acute myeloid leukemia
Daniel J. Chandra, Curtis A. Lachowiez, Sanam Loghavi
Blood Reviews (2023) Vol. 64, pp. 101156-101156
Closed Access | Times Cited: 3
Clinical status of induction therapy incorporating a hypomethylating agent for newly diagnosed adult acute myeloid leukemia compared to the standard 7+3 regimen
Akihiro Ohmoto, Shigeo Fuji
Expert Review of Hematology (2023) Vol. 16, Iss. 10, pp. 761-771
Closed Access | Times Cited: 2
[The guidelines for diagnosis and treatment of relapse /refractory acute myelogenous leukemia in China (2023)].

PubMed (2023) Vol. 44, Iss. 9, pp. 713-716
Closed Access | Times Cited: 2
SOHO State of the Art Updates and Next Questions: Harnessing Apoptosis in AML
Kapil Saxena, Courtney D. DiNardo, Naval Daver, et al.
Clinical Lymphoma Myeloma & Leukemia (2021) Vol. 22, Iss. 3, pp. 133-139
Open Access | Times Cited: 5
IDALLO study: A retrospective multicenter study of the SFGM‐TC evaluating the efficacy and safety of ivosidenib in relapsed IDH1‐mutated AML after allogeneic hematopoietic cell transplantation
Adrien Caillet, Marion Simonet‐Boissard, Édouard Forcade, et al.
HemaSphere (2024) Vol. 8, Iss. 3
Open Access
Transplant Eligible and Ineligible Elderly Patients with AML—A Genomic Approach and Next Generation Questions
Paul Sackstein, Alexis K. Williams, Rachel Zemel, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 975-975
Open Access
Post-Transplant Maintenance Therapy in Acute Myeloid Leukemia
Katherine Parks, Muhammad Faisal Aslam, Vinod Kumar, et al.
Cancers (2024) Vol. 16, Iss. 11, pp. 2015-2015
Open Access
Tumor Metabolism: A New Field for the Treatment of Glioma
Xiaoqian Chai, Yingjie Zhang, Wen Zhang, et al.
Bioconjugate Chemistry (2024) Vol. 35, Iss. 8, pp. 1116-1141
Closed Access
Deciphering the Multifaceted Roles and Clinical Implications of 2-Hydroxyglutarate in Cancer
Jie Hao, Ziyi Huang, Siyue Zhang, et al.
Pharmacological Research (2024) Vol. 209, pp. 107437-107437
Open Access
Feasibility and Safety of Targeting Mitochondria Function and Metabolism in Acute Myeloid Leukemia
Patryk Firmanty, Monika Chomczyk, Shubhankar Dash, et al.
Current Pharmacology Reports (2024)
Open Access
HMA/VEN treatment modifications and associated outcomes in IDH -mutant AML
Kuo-Kai Chin, Andriy Derkach, Christopher Famulare, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024), pp. 1-9
Closed Access
Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine
Mahesh Tambe, S. Herbert Unterberger, Mette C. Kriegbaum, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 10
Open Access
Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia
Maximilian Fleischmann, Madlen Jentzsch, Annamaria Brioli, et al.
Annals of Hematology (2024)
Open Access
The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment
Shan Zheng, Yuxin Tong, Linlin Yang, et al.
Annals of Hematology (2024)
Closed Access
How to improve AML outcomes?
Taner Tan, Sinem Civriz Bozdağ
Blood Research (2024) Vol. 59, Iss. 1
Open Access
Mutation- and MRD-informed treatments for transplant-ineligible patients
Curtis A. Lachowiez, Courtney D. DiNardo
Hematology (2024) Vol. 2024, Iss. 1, pp. 168-177
Closed Access
Progress Toward Epigenetic Targeted Therapies for Childhood Cancer
Athanasia Liapodimitri, Ashley R Tetens, Jordyn Craig-Schwartz, et al.
Cancers (2024) Vol. 16, Iss. 24, pp. 4149-4149
Open Access
Advancing the outcomes of AML out of antecedent MPN by targeting mutated IDH1
Keith W. Pratz
British Journal of Haematology (2024)
Open Access
Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia
Naseema Gangat, Kristen McCullough, Maymona Abdelmagid, et al.
Haematologica (2023)
Open Access
EXABS-178-AML Venetoclax-Based Triplet Regimens in AML
Curtis A. Lachowiez, Courtney D. DiNardo
Clinical Lymphoma Myeloma & Leukemia (2023) Vol. 23, pp. S77-S78
Closed Access
Previous Page - Page 3

Scroll to top